Document:

EX-10.7

 Exhibit 10.7 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly
disclosed. 
 AMENDMENT #2 TO 

EXCLUSIVE LICENSE AGREEMENT 
 This
Amendment #2 (this “Amendment”) is entered into as of February 23, 2018 (the “Amendment Effective Date”) by and between Arena Pharmaceuticals, Inc. (“Licensor”) and Connect Biopharm LLC (“Company”), and
modifies the Exclusive License Agreement dated June 19, 2012 by and between the parties, as amended (the “Existing Agreement” and together with this Amendment, the “Agreement”). 

The parties hereto agree to amend the Existing Agreement in the following respects: 
  

	1.	 The last sentence of Section 10.1(b) of the Existing Agreement is hereby replaced with the following:

 “At any time prior to or contemporaneous with the filing of an answer to the ICC, the other party may, by written
notice to the party initiating binding arbitration, add any related issues to be resolved.” 
  

	2.	 Section 10.10 of the Existing Agreement is hereby replaced with the following in its entirety:

 “10.10 Notices. Any notice or communication required or permitted under this Agreement shall be in writing
in the English language. Any notice must be delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier confirmed thereafter by any of the foregoing, to the party to be notified at its
address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; (b) if
mailed, ten (10) calendar days after the date of postmark; or (c) if delivered by internationally recognized overnight courier, the next business day the courier regularly makes deliveries (taking into consideration the location of the
sending party and the receiving party for international deliveries). 
 If to Company, notices must be addressed to: 

Connect Biopharm LLC 
 12707
High Bluff Drive, Suite 200 
 San Diego CA 92130 

Attention: [***] 
 Telephone:
[***] 
 If to Licensor, notices must be addressed to: 

Arena Pharmaceuticals, Inc. 

6154 Nancy Ridge Drive 

 San Diego, CA 92121 

Attention: General Counsel 

Telephone: [***] 
  

	3.	 Unless otherwise specifically stated herein, all of the terms and conditions of the Existing Agreement shall
remain in full force and effect. The Agreement constitutes and contains the entire agreement of the parties and supersedes any and all prior negotiations, correspondence, understandings, letters of intent and agreements between the parties
respecting the subject matter hereof. The Agreement may be amended or modified or one or more provisions hereof waived only by a written instrument signed by the authorized representatives of the parties. 

 

	4.	 This Amendment shall become binding when any one or more counterparts hereof, individually or taken together,
shall bear the signatures of both parties. This Amendment may be executed by exchange of PDF copies, and in two or more counterparts, each of which will be deemed an original document, and all of which, together with this writing. will be deemed one
instrument. 

 Whereupon, the parties have caused this Amendment to be executed by their duly authorized agents, as of the Amendment
Effective Date. 
  

			
	ARENA PHARMACEUTICALS, INC.	  	 CONNECT BIOPHARM LLC

  

									
	By:	 	 /s/ Katie Cohen

Name: Katie Cohen
 Title: Associate General Counsel
	 		 	    By:	 	 /s/ Zheng Wei

Name: Zheng Wei
 Title: CEO

			
	Date:  26 February 2018	 		 	    Date:  Feb. 24, 2018EX-10.8

 Exhibit 10.8 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly
disclosed 
 AMENDMENT #3 TO EXCLUSIVE LICENSE AGREEMENT 

This Amendment #3 (this “Amendment”) is entered into as of November 19, 2020 (the “Amendment Effective Date”), by and between Arena
Pharmaceuticals, Inc. (“Licensor”) and Connect Biopharm LLC (“Company”), and modifies the Exclusive License Agreement, dated June 19, 2012, by and between the parties, as amended (the “Existing Agreement”, and
together with this Amendment, the “Agreement”). 
 The parties hereto agree to amend the Existing Agreement in the following respects: 

 

	1.	 EXHIBIT A—“Licensed Patents as of the Effective Date” is replaced in its entirety with EXHIBIT
A—“Licensed Patents as of the Amendment Effective Date” attached hereto. 

  

	2.	 The following definitions are hereby added to Section 1 (DEFINITIONS) of the Existing Agreement:

 “Marketing Authorization Application” or “MAA” shall mean any new drug application
filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially market or sell a pharmaceutical product in such country or jurisdiction (and any amendments thereto). In the
context of imported drugs, MAA is also known as the Import Drug License (“IDL”) application. 
 “Marketing Authorization
Holder (MAH)” shall mean, with respect to any country, any party or Affiliate thereof who is the holder a Regulatory Approval in such country. 

“MAA Approval” shall mean with respect to a particular country or other regulatory jurisdiction, any approval of an MAA or
other approval, product, or establishment license, registration, or authorization of any Regulatory Authority necessary for the commercial marketing or sale of a pharmaceutical product in such country or other regulatory jurisdiction, excluding, in
each case, any pricing and reimbursement approvals. Any reference to “regulatory approval” in this Agreement shall also be deemed to be an MAA Approval for purposes of this Agreement. 

 

	3.	 Section 2.1 of the Existing Agreement is hereby replaced in its entirety with the following:

 “Section 2.1 License Grant. Subject to the terms of conditions of this Agreement,
Licensor hereby grants to Company, during the term of this Agreement, an exclusive (even as to Licensor, except for internal research purposes), worldwide, royalty-bearing license under the Licensed Technology and the Program Technology to identify,
research, develop, make, have made, use, sell, offer for sale, have sold and import Products (the “License”). Unless expressly prohibited by Applicable Laws in a country, the Company or its Affiliate or sublicensee shall be the Marketing
Authorization Holder (MAH) for a Product in each county in which Company or its Affiliate sells such Product. Company or its Affiliate or its sublicensee will own and solely maintain all MAA Approvals for the Products.” 

  
 1 

	4.	 Unless otherwise specifically stated herein, all of the terms and conditions of the Existing Agreement shall
remain in full force and effect. The Agreement constitutes and contains the entire agreement of the parties and supersedes any and all prior negotiations, correspondence, understandings, letters of intent and agreements between the parties
respecting the subject matter hereof. The Agreement may be amended or modified or one or more provisions hereof waived only by a written instrument signed by the authorized representatives of the parties. 

 

	5.	 This Amendment shall become binding when one or more counterparts hereof, individually or taken together, shall
bear the signatures of both parties. This Amendment may be executed by exchange of PDF copies, and in two or more counterparts, each of which will be deemed an original document and all of which, together with this writing, will be deemed one
instrument. 

 Whereupon, the parties have caused this Amendment to be executed by their duly authorized agents, as of the
Amendment Effective Date. 

 

			
	ARENA PHARMACEUTICALS, INC.

			
	By:	 	 /s/ Vincent Aurentz

			
	Name: Vincent Aurentz
	Title: EVP & CBO
	Date: Nov 20, 2020 | 8:58 AM PST

			
	CONNECT BIOPHARM LLC

			
	By:	 	 /s/ Zheng Wei

			
	Name: Zheng Wei
	Title: CEO
	Date: Nov 20, 2020 | 9:16 AM PST

 
 

  
 2 

 Exhibit A 

Licensed Patents as of the Amendment Effective Date 

[***] 

  
 3EX-10.9

 Exhibit 10.9 

House Lease Contract 
 Lessor: Taicang
Science and Technology Venture Park Co., Ltd. (hereinafter referred to as “Party A”) 
 Lessee: Suzhou Connect Biopharmaceuticals, Ltd.
(hereinafter referred to as “Party B”) 
 In accordance with the “Contract Law of the People’s Republic of
China” and relevant provisions, in order to define the rights and obligations of the Lessor and the Lessee, Party A and Party B hereby sign this Contract upon negotiated consensus. 

Article 1 Party A will lease the 3rd floor of the 2# R&D Building at No. 6 West Beijing Road, Taicang City, to Party B for the
company’s office use, with a house area of 1,611.63 m2. 
 Article 2 Lease
period: from March 1, 2019 to February 28, 2022. 
 When the lease contract is
terminated upon expiration, if Party B proposes the renewal of the contract, it shall notify Party A of its intention to renew the contract in writing one month before the expiration of the contract. After the contract expires, if Party A continues
to lease out the house, Party B shall have priority. 
 Article 3 House rent and consultation & technical service fee 

The rent will be RMB 23/m2•month, and the consultation & technical
service fee will be RMB 3/m2•month. 
 Mode of payment: quarterly payment;
the rent and consultation & technical service fee for one month shall be paid as a security deposit within five working days from the signing date of the contract, and meanwhile, the rent and consultation & technical service fee
for three months shall be paid (subsequently, every three months shall be a payment cycle). The rent and consultation & technical service fee for the next cycle, i.e., three months, shall be paid 15 days before the expiration of the 3rd
month of the first cycle, and the rest may be deduced by analogy. 
 After Party B’s payment, Party A shall issue a general value-added
tax invoice. 
 Article 4 Party A’s rights and obligations 

1. Party A shall provide intact office house, and guarantee the supply of water and electricity. In case of any failure, Party A shall solve it
in a timely manner. The water & electricity fee shall be borne by Party B and withheld and paid by Party A, and Party B shall make payment in a timely manner according to Party A’s provisions. 

2. Party A shall be responsible for the repair of the house to ensure Party B’s normal and safe use. Party A shall be responsible for the
management services of public areas. 
 3. If there are the factors beyond Party A’s control that cause the instability or interruption
of services such as water, electricity, network, etc., Party A need not assume any responsibility, but shall try its best to take effective measures to reduce the influences and losses caused thereby. 

Article 5 Party B’s rights and obligations 

1. Party B shall not sublease, transfer, or lend the house arbitrarily, and shall not use the house for
non-office use (warehouse, dormitory, etc.). 
 2. Party B shall not use the leased house to conduct
illegal activities and harm public interests. 
 3. Party B shall guarantee to comply with the “Interim Regulations on Property
Management of the Incubation Building”, the “Interim Regulations on Renovation Management” and other relevant provisions on property management formulated by Party A. 

[seal:] Taicang Science and Technology Venture Park Co., Ltd. [illegible] 

[seal:] Suzhou Connect Biopharmaceuticals, Ltd. 3205851965705 

 1. If Party B renovates the house due to business needs, it shall not damage the structure
and appearance of the house, and the outdoor unit of air conditioner shall not be hung outdoors without authorization and shall be placed at a designated location in the park; if the renovation involves the construction and modification of fire
safety, it needs to declare to the relevant management department independently according to national provisions; Party B shall submit a plan to Party A in writing before the renovation, which may be implemented only after Party A gives its consent,
otherwise Party B must bear the economic losses caused thereby. Party B needs to comply with the relevant regulations on renovation management formulated by Party A. 

2. The elevators, stairs, passages, and other public spaces on this floor shall be shared by all users, and Party B shall not hinder the use of
others. 
 3. Party B shall pay house rent, consultation & technical service fee and other expenses on time. 

4. Party B shall comply with other provisions of Party A’s management department. 

5. Party B shall strictly abide by the Chinese laws and regulations on the protection of intellectual property rights, and assume the legal
liability for any infringement or violation of intellectual property rights independently. 
 6. When this Contract is terminated, or when
Party B leaves the park in advance, Party B must settle the house rent and consultation & technical service fee in a timely manner. Party B shall promise that all items in the office site will not be removed before all expenses have been
settled. In the event of forcible removal, Party A shall have the right to interfere. In the event of any losses to Party A, it shall be handled according to Paragraph 3, Article 6. 

7. When this Contract is terminated, Party B shall remove all items belonging to Party B in the leased site, including interior renovation and
various equipment, and restore the site to its original state at its own expense. If Party B fails to restore the leased site to its original condition, the interior renovation (such as partitions, doors, windows, etc.) shall not be dismantled or
damaged. 
 After the site is returned to Party A, Party A may freely dispose of the items used and left by Party B in the leased site. 

8. When this Contract is terminated, if Party B is unable to return the leased site in a timely manner, from the next day after the termination
date of the contract until the return date of the leased site, Party B shall pay Party A a liquidated damage equivalent to two times of the monthly rent and other expenses. At the same time, if Party A suffers other losses, Party B shall also pay
compensation. 
 9. When Party B returns the leased site, it shall not require Party A to purchase the interior renovation and various
equipment funded by Party B. 
 10. Party B shall assist Party A in the management work and publicity, education, and cultural activities of
the venture park; cooperate on the statistical work of the venture park, and report the relevant statistics of technological enterprise incubator required by the relevant national and local departments to the venture park in a timely manner. 

Article 6 If Party B has one of the following circumstances, Party A can terminate the contract, stop the supply of water &
electricity and other service guarantees, and recover the house (Party B shall bear and be responsible for all losses caused thereby, including Party B’s renovation, etc.): 

1. Party B subleases, transfers, or lends the house arbitrarily; 

2. Party B uses the leased house to conduct illegal activities and harm public interests; 

3. Party B delays the arrears of rent and consultation & technical service fee for two months (due to Party B’s delay in the
arrears of rent, consultation & technical service fee, etc., with the result of causing Party A’s losses, Party B shall agree to Party A’s free disposal of the office furniture, office supplies and other assets left by Party B in
the house to cover the arrears owed by Party B, and Party A shall reserve the right to investigate the legal liability of Party B). 
 [seal:] Taicang
Science and Technology Venture Park Co., Ltd. [illegible] 
 [seal:] Suzhou Connect Biopharmaceuticals, Ltd. 3205851965705 

 Article 7 Change of the Lessor and the Lessee 

1. If Party A transfers the ownership of the house to any third party, the contract shall continue to be valid for the new owner of the house.

 2. If Party A sells the house, it must notify Party B three months in advance. 

3. If Party B terminates the contract in advance, it shall notify Party A in writing one month in advance. After the settlement of expenses
between both parties, Party A shall return Party B’s security deposit. 
 Article 8 Liability for violation of contract 

1. If either party terminates the contract in advance without justifiable reasons and causes economic losses to the other party, it shall pay
compensation. 
 2. If the Lessee delays the payment of rent, in addition to making up the payment in a timely manner, it shall pay a
liquidated damage at a daily rate of 0.05% from the date when the payment is delayed. 
 Article 9 Conditions for disclaimer of liability

 If the house is destroyed due to force majeure, with the result of causing Party A’s losses, both parties shall not be liable to each
other. 
 Article 10 Conditions for dispute resolution 

If there is any dispute during the performance of this Contract, both parties shall resolve it through negotiation; if the negotiation fails,
they may file a lawsuit with the Taicang People’s Court. 
 Article 11 The matters not covered in this Contract shall be subject to the
relevant provisions of the “Contract Law of the People’s Republic of China”, and supplementary provisions shall be made after the mutual negotiation between both parties to the contract. The supplementary provisions shall have the
same effect as this Contract. 
 This Contract shall be made in quadruplicate, and both parties shall hold two copies respectively. 

 

			
	Party A: Taicang Science and Technology Venture Park Co., Ltd.	  	Party B: Suzhou Connect Biopharmaceuticals, Ltd.
	Agent (Signature): /s/ [STAMPED]	  	Legal Representative (Signature): /s/ [STAMPED]
	[seal:] Taicang Science and Technology Venture Park Co., Ltd. 3205850937840	  	[seal:] Suzhou Connect Biopharmaceuticals, Ltd. 3205851965705
		
	  
 (Month) (Day) (Year)
	  	 February 1, 2019

(Month) (Day) (Year)

		
	 [seal:] Taicang Science and Technology Venture Park Co., Ltd. 3205850937840
(太仓市科技创业园有限公司)
	  	[seal:] Suzhou Connect Biopharmaceuticals, Ltd.
3205851965705 (苏州康乃德生物医药有限公司)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]